| Old Articles: <Older 6921-6930 Newer> |
 |
The Motley Fool November 30, 2010 Seth Jayson |
Don't Get Too Worked Up Over Agilent Technologies' Earnings With questionable cash flows amounting to only -0.7% of operating cash flow, Agilent Technologies' cash flows look clean.  |
The Motley Fool November 30, 2010 Brian Orelli |
Nice Data; Still a Long Wait for the Payoff It may not be enough to move Keryx Biopharmaceuticals' Zerenex to blockbuster status, but the data from a phase 3 trial released today sure look good enough to get it on the market.  |
The Motley Fool November 30, 2010 Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.  |
The Motley Fool November 30, 2010 Brian Orelli |
This Fish Oil Is No Snake Oil So far, Amarin's AMR101 looks like a wonder drug, and its potential is huge.  |
The Motley Fool November 30, 2010 Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices.  |
The Motley Fool November 29, 2010 Seth Jayson |
Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years.  |
The Motley Fool November 29, 2010 Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.  |
The Motley Fool November 29, 2010 Seth Jayson |
Check This to Find Out Whether Orthovita Is Going to Bomb For the last fully reported fiscal quarter, Orthovita's year-over-year revenue grew 4.6%, and its AR grew 9.2%. That looks OK.  |
The Motley Fool November 29, 2010 Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.  |
The Motley Fool November 29, 2010 Travis Hoium |
Protalix BioTherapeutics Shares Popped: What You Need to Know Shares of biopharmaceutical company Protalix BioTherapeutics jumped 10% this morning after the company announced a European application for taliglucerase alfa.  |
| <Older 6921-6930 Newer> Return to current articles. |